BRCA2 and ovarian cancer: We present our experience and findings of implementing a cancer multidisciplinary team (MDT) coordinated mainstreaming pathway of unselected 5-panel germline BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and parallel somatic BRCA1/BRCA2 testing in all women with high grade non-mucinous epithelial OC in the Systematic Genetic Testing for Personalised Ovarian Cancer Therapy (SIGNPOST) study (ISRCTN: 16988857) in women from North East London Cancer Network (NELCN).